Skip to main content

NATIXIS

Position in LLY — ELI LILLY & Co

CIK 1274981 PARIS, I0

Position in LLY

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$92,848,022
-$127,463,547 QoQ
Shares Held
100,947
-50.8% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.49%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in LLY Over Time

Shares Held

Position Value (USD)

Derivatives in LLY

reported options exposure · as of Mar 31, 2025
CallValue
$0
CallShares
0
PutValue
$82,591,000
PutShares
100,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Mar 31, 2026

NATIXIS holds $547,855,762 across 11 Drug Manufacturers - General names. LLY ranks #2 (16.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
2 LLY
ELI LILLY & Co
This page
100,947 $92,848,022

All Filings in LLY

Export CSV
28 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $92,848,022 100,947
2025-12-31 $220,311,569 205,002
2025-09-30 $186,429,894 244,338
2025-06-30 $188,687,575 242,053
2025-03-31 $271,328,779 328,521
2025-03-31 $82,591,000 100,000
2024-12-31 $106,516,700 137,975
2024-09-30 $205,540,737 232,003
2024-06-30 $143,179,509 158,143
2024-03-31 $172,330,587 221,516
2023-12-31 $92,020,917 157,862
2023-09-30 $118,446,833 220,518
2023-06-30 $164,177,235 350,073
2023-03-31 $17,557,004 51,124
2022-12-31 $74,354,053 203,242
2022-09-30 $2,263 7
2022-09-30 $110,199,943 340,807
2022-06-30 $3,890 12
2022-06-30 $40,894,805 126,129
2022-03-31 $79,462,806 277,483
2021-12-31 $35,968,539 130,217
2021-09-30 $17,774,214 76,928
2021-06-30 $21,452,775 93,468
2021-03-31 $4,296,673 22,999
2020-12-31 $61,884,249 366,526
2020-09-30 $33,833,375 228,573
2020-06-30 $25,526,213 155,477
2020-03-31 $2,230,756 16,081